October 12th-14th & 19th-20th : Defymed at the Cell and Gene meeting on the MESA 2021
Defymed will be participating digitally to the Cell & Gene Meeting on the Mesa 2021 that will be delivered in a hybrid format. This event is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
As Defymed’s medical devices are positionned as platforms, this meeting is of great interest to to find strategic partners, more specifically for the MailPan® cell-encapsulation device, in diverse cell-therapy applications, such as diabetes, hemophilia, lysosomal diseases or alzheimer. Defymed will be looking to learn more about the hurdles cell therapy is facing in other applications than Diabetes, but also on recent advances towards a future commercialization of cell therapy in the major markets. This includes the status of upscaled manufacturing, pricing and market access strategies. Topics on clinical and regulatory requirements will also be followed. Defymed’s Chief Operating Officer, Richard Bouaoun, will be happy to meet you during the BtoB digital sessions held on October 19th and October 20th in order to discuss potential strategic partnerships or investment opportunities.
For more info about the Cell and Gene Meeting on the MESA 2021